3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Colonic Neoplasms
4
Rectal Neoplasms
3
Pancreatic Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
1
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
1
Somatostatinoma
1
Salivary Gland Neoplasms
1
Pancreatic Intraductal Neoplasms
1
PRETEXT I Hepatoblastoma
1
Oropharyngeal Neoplasms
1
Lymphoid Interstitial Pneumonia
1
Klatskin Tumor
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
DNA Repair-Deficiency Disorders
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Bile Duct Neoplasms
1
Anus Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
dehydroftorafur
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts